About: COVID‐19 in kidney transplant recipients: A multicenter experience in Istanbul

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: COVID‐19 in kidney transplant recipients: A multicenter experience in Istanbul Goto Sponge NotDistinct Permalink

An Entity of Type : schema:ScholarlyArticle, within Data Space : covidontheweb.inria.fr associated with source document(s)

Attributes	Values
type	Academic Article research paper schema:ScholarlyArticle
isDefinedBy	Covid-on-the-Web dataset
has title	COVID‐19 in kidney transplant recipients: A multicenter experience in Istanbul
Creator	Ahmet, \| Akin, Baris Ali, \| Aydin Turkmen, \| Demir, Emin Demir, Erol Dirim, Burak Emin, \| Garayeva, Nurana Mehmet, \| Mese, \| Murathan Uyar, \| Oto, Akin Ozgur Merhametsiz, \| Ozgur, \| Parmaksiz, \| Safak, Seda Serap Yadigar, \| Sinangil, Ayse Ucar, Atan Ucar, Riza Yazici, Halil Yelken, Berna Zuhal, \|
Source	Medline; PMC
abstract	INTRODUCTION: Management of COVID‐19 in kidney transplant recipients should include treatment of the infection, regulation of immunosuppression, and supportive therapy. However, there is no consensus on this issue yet. This study aimed to our experiences with kidney transplant recipients diagnosed with COVID‐19. MATERIAL AND METHODS: Kidney transplant recipients diagnosed with COVID‐19 from five major transplant centers in Istanbul, Turkey, were included in this retrospective cohort study. Patients were classified as having moderate or severe pneumonia for the analysis. The primary endpoint was all‐cause mortality. The secondary endpoints were acute kidney injury, the average length of hospital stay, admission to intensive care, and mechanical ventilation. RESULTS: Forty patients were reviewed retrospectively over a follow‐up period of 32 days after being diagnosed with COVID‐19. Cough, fever, and dyspnea were the most frequent symptoms in all patients. The frequency of previous induction and rejection therapy was significantly higher in the group with severe pneumonia compared to the moderate pneumonia group. None of the patients using cyclosporine A developed severe pneumonia. Five patients died during follow‐up in the intensive care unit. None of the patients developed graft loss during follow‐up. DISCUSSION: COVID‐19 has been seen to more commonly cause moderate or severe pneumonia in kidney transplant recipients. Immunosuppression should be carefully reduced in these patients. Induction therapy with lymphocyte‐depleting agents should be carefully avoided in kidney transplant recipients during the pandemic period.
has issue date	2020-07-13(xsd:dateTime)
bibo:doi	10.1111/tid.13371
bibo:pmid	32657540
has license	no-cc
sha1sum (hex)	d61851a09429015fdf01d3794c8eb8d32d21b4b6
schema:url	https://doi.org/10.1111/tid.13371
resource representing a document's title	COVID‐19 in kidney transplant recipients: A multicenter experience in Istanbul
has PubMed Central identifier	PMC7404438
has PubMed identifier	32657540
schema:publication	Transpl Infect Dis
resource representing a document's body	covid:d61851a09429015fdf01d3794c8eb8d32d21b4b6#body_text
is schema:about of	named entity 'intensive care' named entity 'kidney transplant' named entity 'MAJOR' named entity 'SEVERE PNEUMONIA' named entity 'EXPERIENCES' named entity 'Management' named entity 'severe' named entity 'Turkey' named entity 'major' named entity 'stay' named entity 'multicenter' named entity 'primary endpoint' named entity 'COVID' named entity 'acute kidney injury' named entity 'COVID' named entity 'Istanbul' named entity 'COVID-19' named entity 'COVID' named entity 'lung' named entity 'mechanical ventilation' named entity 'favipiravir' named entity 'hydroxychloroquine' named entity 'Calcineurin' named entity 'critical point' named entity 'bacterial infection' named entity 'Induction therapy' named entity 'RT-PCR' named entity 'CRP' named entity 'azithromycin' named entity 'radiographic' named entity 'induction therapy' named entity 'organ dysfunction' named entity 'lactate dehydrogenase' named entity 'nasal cannula' named entity 'COVID' named entity 'lactate dehydrogenase' named entity 'dry cough' named entity 'toxicity' named entity 'LDH' named entity 'confidence intervals' named entity 'mTOR' named entity 'standard deviations' named entity 'RNA' named entity 'Oxygen' named entity 'radiology' named entity 'favipiravir' named entity 'prospective cohort studies' named entity 'arrhythmia' named entity 'Wuhan' named entity 'loss to follow-up' named entity 'aspartate aminotransferase' named entity 'kidney transplant' named entity 'anti-rejection therapy' named entity 'interquartile range' named entity 'Istanbul Faculty of Medicine' named entity 'immunological' named entity 'pneumonia' named entity 'risk factor'

Faceted Search & Find service v1.13.91 as of Mar 24 2020

Alternative Linked Data Documents: Sponger | ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3229 as of Jul 10 2020, on Linux (x86_64-pc-linux-gnu), Single-Server Edition (94 GB total memory)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2024 OpenLink Software